EHC - European Haemophilia Consortium/LinkedIn
Oct 1, 2025, 16:30
Emicizumab Approvals in Europe: European Haemophilia Consortium Shares Key Updates
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Indications of non-factor treatments for haemophilia A are evolving.
In Europe, Emicizumab is approved for routine prophylaxis for moderate haemophilia A with severe bleeding, for severe haemophilia A and for haemophilia A with factor VIII inhibitors.
It is always a good idea to consult local regulatory authorities for the precise current approved use in your area.
Learn more in the EHCucate topic Emicizumab Basics, available on the EHC Academy.”
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator